Bellicum Pharmaceuticals Announces Aggregate Gross Proceeds of $69.6 Million from $139.6 Million Public Offering and Private Placement
August 21, 2019 16:05 ET
|
Bellicum Pharmaceuticals, Inc.
HOUSTON, Aug. 21, 2019 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq: BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood...
CORRECTING and REPLACING - Bellicum Pharmaceuticals, Inc.
August 16, 2019 10:52 ET
|
Bellicum Pharmaceuticals, Inc.
Bellicum Pharmaceuticals Announces Pricing of $139.6 Million Public Offering and Private Placement Pricing of $57.5 Million Public Offering of Preferred Stock and Warrants and Entry into Concurrent...
Bellicum Pharmaceuticals Announces Pricing of Bellicum Pharmaceuticals Announces Pricing of $139.6 Million Public Offering and Private Placement
August 16, 2019 08:30 ET
|
Bellicum Pharmaceuticals, Inc.
HOUSTON, Aug. 16, 2019 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq: BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood...
Bellicum Pharmaceuticals Announces Proposed $53.0 Million Public Offering of Preferred Stock and Warrants with Concurrent Private Placement
August 15, 2019 17:37 ET
|
Bellicum Pharmaceuticals, Inc.
HOUSTON, Aug. 15, 2019 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq: BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood...
Precipio Pathology Sales Metrics Demonstrate Continuous Improvement in Q2 2019
August 13, 2019 11:30 ET
|
Precipio, Inc.
NEW HAVEN, Conn., Aug. 13, 2019 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), today announced the results of three key performance metrics that together...
Autolus Therapeutics Reports Second Quarter 2019 Financial Results and Operational Progress
August 08, 2019 07:49 ET
|
Autolus Therapeutics plc
LONDON, Aug. 08, 2019 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced...
Incysus Therapeutics Strengthens Board of Directors With Appointment of Pharmaceutical Veteran Peter C. Brandt
August 06, 2019 07:00 ET
|
Incysus Therapeutics, Inc.
NEW YORK, Aug. 06, 2019 (GLOBE NEWSWIRE) -- Incysus Therapeutics, Inc. (“Incysus”), a biopharmaceutical company focused on delivering an innovative gamma-delta (γδ) T cell immunotherapy for the...
Bellicum Pharmaceuticals Reports Second Quarter 2019 Financial Results and Provides Operational Update
August 05, 2019 16:15 ET
|
Bellicum Pharmaceuticals, Inc.
Interim safety and activity data for BPX-601 presented at American Society of Clinical Oncology (ASCO) Annual Meeting Rivo-celTM achieved primary endpoint in BP-004 European registrational trial ...
Bellicum Pharmaceuticals Announces Rivo-cel™ Achieves Primary Endpoint in Pediatric Registrational Trial
July 08, 2019 08:00 ET
|
Bellicum Pharmaceuticals, Inc.
Primary endpoint of event free survival (EFS) rate at 180 days of 90.9 percent reported for rivo‑cel in BP-004 European registrational trial Investigational trial results support potential that...
Incysus Therapeutics Appoints Rozanna Yaing As Senior Vice President, Quality And Regulatory Affairs
July 02, 2019 08:00 ET
|
Incysus Therapeutics, Inc.
NEW YORK, July 02, 2019 (GLOBE NEWSWIRE) -- Incysus Therapeutics, Inc. (“Incysus”), a biopharmaceutical company focused on delivering an innovative gamma-delta (γδ) T cell immunotherapy for the...